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Abstract 
Systemic sclerosis (SSc) is one of autoimmune diseases that affected multiorgans, clinically showed that the 
extensive skin and internal organs fibrosis. Systemic sclerosis showed that the three basic sorts: autoimmunity, 
inflammation, vasculopathy. This study was design to investigate the changes of anti-topoisomerase I antibody 
(Scl-70) and Anti-Ro (SSA) in the whole saliva and serum of patients with SSc. There were highly significant (p< 
0.001) elevation in Scl-70 antibody in serum and non-significant difference in saliva of patients with systemic 
sclerosis with median and mean rank (215.91, 51.80, 228.43 and 37.13 ng/ml respectively) in compares with 
control subject. The mean level of serum SSA in SSc patient (140.4 ± 22.67) ng/ml  that it was significant increased 
(p< 0.001) as well as the mean level of salivary SSA in SSc patient (145.5 ± 19.98) ng/ml  was highly significantly 
increased in compares with control subject. 
Keywords:  Anti topoisomerase antibody (Scl-70), SSA (anti-Ro), SSc. 
 
1. Introduction 
Systemic sclerosis (SSc) is a multiorgan illness with immune-mediated of unidentified cause considered by 
progressive fibrosis of skin and internal organs, with occurrence of a set of specific auto reactive antibodies (Varga 
and Abraham, 2007). The most important autoantibodies appeared significantly in SSc patients are anti-
topoisomerase I autoantibody (Scl-70), anti-centromere autoantibody (ACA), and anti-RNA polymerase III 
autoantibody (RNAP3) (Steen, 2005). SSc was classify into two main types, according to the extent of skin 
involvement. (Khanna and Denton, 2010). 
1. Limited cutaneous systemic sclerosis (lcSSc) 
2. Diffuse cutaneous systemic sclerosis (dcSSc)  
Systemic sclerosis was classified in subdivision by LeRoy et al., 1988 as firstly limited type SSc when 
the skin involved up to the elbow and knees with the face – and in diffuse form SSc – with skin envelopment also 
including the trunk. There are three main features of SSc, which integrated by 2013 SSc criteria but not all patients, 
come with these feature:  autoantibodies, vascular injury, and finally with fibrotic changes. Raynaud phenomenon 
(RP) is a feature included in SSc criteria if distinguished from other disease associated with RP, but because SSc 
without RP is so infrequent, so raynaud phenomenon augmented statistical significance to this criteria (Van den 
hoogen et al., 2013). The criteria of SSc in 2013 can be demarcated principles and classify more patients with SSc 
such as a patient with Raynaud phenomena, sclerodactyly,  anticentromere  antibody,  and  established  pulmonary 
arterial hypertension would be categorized as having SSc by criteria of rheumatism  in  2013 but  not  by  the  1980  
criteria (Van den hoogen  et al., 2013).  
There are some features associated with SSc patient such as sclerodactyly, anticentromere antibodies, 
Scl-70, Raynaud phenomena, dilated nailfold capillaries, dysphagia, and calcinosis. However, a  patient  with  only  
sclerodactyly,  gastroesophageal  reflux  disease, dysphagia,  RNA  polymerase  III and  renal crisis would not 
encounter either usual of SSc criteria,  but as soon as  the  scleroderma  advanced  beyond  the  fingers,  the patient 
would fulfil both classifications. The  2013  SSc  classification  criteria  may  need  some description  and  
clarification (Van den hoogen  et al., 2013).  
SSc pathophysiology is very multifaceted and incompletely clear. It’s branded by various histological 
and cellular abnormalities, such as endothelial cells, fibroblasts, and cells of the immune systems such as 
“monocytes/macrophages, dendritic cells, and lymphocytes”. Endothelial dysfunction is early appears to be the 
inducing factor, with endothelial activation triggered by anti-endothelial cells antibodies. Vasoconstriction is 
promoted by endothelial dysfunction due to endothelin-1 synthesis as an endogenous vasoconstrictors and 
decreasing endothelial vasodilators like nitric oxide and prostacyclin. Vasoconstriction modifies tissue 
oxygenation and the resulting hypoxia stimulates VEGF production, charted by reduction of progenitor endothelial 
cells. Cytokines derived from endothelial dysfunction (e.g. endothelin-1 and thrombin) exert direct fibrogenic 
effects by enhancing the proliferation and transformation of fibroblasts into myofibroblasts (Hua-Huy and Dinh-
Xuan, 2016).  
The real cause of systemic sclerosis (SSc) disease remains unidentified, but it is showed that the 
abnormalities in B cell characterized by autoantibody creation (Okano, 1996). 
Abnormalities in blood homeostasis and B cell have been considered by activation and expansin of naive 
cells, but memory B cells reduced, as well as hyper-globulinemia and polyclonal B cell hyperactivity are thought 
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to be dramatic role in SSc illness furthermore, autoantibody production controlled by appearance of CD19, a 
serious B cells transduction signal molecule, that it is suggestively increased production and hyperactivity of naïve 
B cells in SSc patients (Sato et al., 2000; Sato et al., 2004). Thus, B cells was considered a significant influence 
on the fibrotic changes and growth development as labelled in scleroderma mouse models (Yoshizaki et al., 2008). 
The attendance of serum autoantibodies attacked to many intracellular antigens is a serological hallmark 
of SSc, more than 95% of these autoantibodies are presented in SSc patients as a supportive biomarkers for 
instituting an accurate early diagnosis of such disease with interesting that they are also associated with individual 
clinical divisions, exact patterns of organ envelopment, and different predictive features (Arnett et al., 2010; Mehra 
et al., 2013).  
Anti-topoisomerase 1 (Scl-70), anti-centromere (ACA), and anti-RNA polymerase III are considered 
highly specific for SSc, and these were added to League against Rheumatism (ACR/EULAR) SSc classification 
criteria of the 2013 American College of Rheumatology/European (Van den hoogen et al., 2013). 
Anti-topoisomerase antibodies (Scl-70) are auto reactive antibodies focused toward topoisomerase 
enzyme that it is initiate in some diseases, most prominently in SSc as well as any diseases with Scl-70 positive. 
SSc is an autoimmune disease because of they reacted with self-proteins. They are also represented to as anti-DNA 
topoisomerase I antibody as a types of anti-nuclear autoantibody realized mainly in diffuse systemic sclerosis, but 
it is also seen in the more limited form of systemic sclerosis (CREST syndrome). Anti Scl-70 antibodies are related 
with more severe scleroderma disease (Mitchell et al., 2007). Classification of anti-topoisomerase antibodies can 
be rendering to their immunoglobulin class (IgM, IgG, and IgA). IgG class is commonly present in scleroderma, 
with IgA being fairly mutual but IgM very rare (Hildebrandt et al., 1990). 
The strain on DNA relaxed by topoisomerase I enzyme that nicking and ligating the DNA. Anti-
topoisomerase I antibodies (Scl-70) prevents the enzyme activity, because of this action happens in the cell nucleus, 
therefore Scl-70 is anti-nuclear antibody. SSc is determined by increasing collagen deposition in affected tissues, 
some studies prerogatives that there are an increasing topoisomerase I concentration in sites of the collagen genes, 
and that the transcription at these loci may be changes. Scl-70 associated with fast disease development as well as 
Scl-70 autoantibody in systemic lupus erythematosus are allied with nephritis (Hamidou et al., 2006; Perera et al., 
2007).  
Scl-70 autoantibodies are strappingly related to dcSSc and an unfortunate prognosis. Nonetheless, Scl-
70 have also been described in patients with lcSSc. Systemic sclerosis patients with Scl-70 positive have a higher 
risk of cardiac and severe pulmonary envelopment. Scl-70 autoantibodies also related to joint involvement, digital 
ulcers, and tendon rubbing. The renal crisis has been reported but not reliably found in all SSc allies. Additionally, 
the existence of Scl-70 autoantibodies with Raynaud’s phenomenon is prognostic in that they are concomitant with 
SSc development (Steen, 2005). 
At least two diagnostic criteria of connective tissue diseases is established to diagnosis overlap syndrome. 
The most common association of systemic sclerosis with “Sjogren's syndrome, dermatomyositis or polymyositis, 
rheumatoid arthritis, and systemic lupus erythematosus”. Primary Sjogren's syndrome is mutual with SSc about 
“68%”, but the criteria of Sjogren’s syndrome is achieve only in 14% of SSc patients (Balbir-Gurman and Braun-
Moscovici, 2011). 
One hundred and eighteen SSc patients were included in previous study. All SSc patients were 
questioned with respect to sicca symptoms. Levels of rheumatoid factor (RF), anti-nuclear antibodies (ANA), and 
anti-Ro and anti-La antibodies were measured; non-stimulated saliva amounts were recorded and Schirmer test 
and break-up time were applied to all patients. Minor salivary gland biopsy samples were obtained from those 
patients giving ≥ 3 positive answers to sicca symptom questions, patients with positive xerostomia/xerophthalmia 
test results, and patients with at least one antibody being positive. Patients presenting with grade 3 and/or grade 4 
sialoadenitis based on Chisholm criteria were considered pathological (Kobak et al., 2013). 
 
2. Material and Methods: 
This study carried out during the period from the middle of November 2015 until the end of March 2016 in 
Baghdad city, the sample of this study divided into two groups: 
1- Forty systemic sclerosis patients: Those patients treated at Rheumatology department in Bagdad teaching 
hospital in Baghdad city.  
2- Forty healthy control subjects, age matched with no signs and symptoms of any systemic diseases.  
All patients diagnosed by a Rheumatology specialist as systemic sclerosis patients depending on the 
criteria of the ACR, 2013. All the subjects  answered a written questionnaire regarding their name, age, gender, 
occupation, dental  and medical histories, regularity of tooth-brushing, feeling of dry mouth and bad breath, any 
oral, dental and systemic diseases, complete medical history with clinical and physical examinations for each 
individual included in this study was performed by Rheumatologist. 
Whole resting (Unstimulated) saliva was gathered under inactive circumstances ranged from 8.0-11.0 a.m. 
Any oral hygienic procedure should be avoided and patients were asked to clean their mouth with water, create 
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saliva in their oral cavity and spit into a test tube (Navazesh, 1993).  
The resulting supernatant from centrifuged saliva was stored at -20 °C in polyethylene tubes until analyzed. 
Saliva was centrifuge at “3000 rpm” for 10 minutes.  
Serum sample: 
About 5 ml of venous blood samples permitted to clot at room temperature for 2 hours, from each subject before 
centrifugation for 15 minute at 1000 rpm. Blood collection tubes should be disposable, non-pyrogenic, and non-
endotoxin 
The quantitative determination of Human anti-SSA/Ro ELISA Kit used from Kono biotech Co. LTD 
company. 
Proposed use:  
For content determination in “serum, plasma, cell culture supernatant, tissue homogenate and any other biological 
fluid”. 
The quantitative determination of Human Scl-70 (anti-topoisomerase) ELISA Kit used from Kono 
biotech Co. LTD Company. 
Proposed use: For content determination in “serum, plasma, cell culture supernatant, tissue homogenate and any 
other biological fluid”. 
 
2.2 Statistical analysis 
The documents data transformed into a computerized record structure. A professional statistical guidance was 
sought for statistical analyses and computer aided by using “SPSS version 21.0 Statistical Package for Social 
Sciences”. The statistical analysis includes:  
• Descriptive statistic: The quantitative result was tested by Kolmogorov-Smirnov Z test to determine 
whether these data was parametric or non-parametric. The normally distributed data (parametric data) 
was suitably described by “mean, standard deviation (SD)” while non-parametric data was suitably 
described by “median and mean Rank”    
• Inferential statistic: These were used in order to accept or reject the statistical hypothesis.  
 Independent sample t-test was used to test statistical differences between two parametric 
groups. 
 Mann-Whitney test was used to test statistical differences between two non-parametric groups. 
 
3. Results and Discussion 
In present study, the median and mean rank level of serum Scl-70 in SSc patients (215.91and 51.80) ng/ml  using 
Mann-Whitney U test the data was reveal highly significantly increased (P<0.001) than that control group. 
Serum autoantibodies are reflected the main biomarkers for the early and accurate diagnosis of SSc as 
well as related to individual clinical subsets and diverse prognostic features. Although SSc-related autoantibodies 
were historically considered to be commonly exclusive. 
Serum Scl-70 increased in patients with SSc. This comes in agreement with (Reveille and Solomon, 
2003). 
The median and mean rank level of salivary Scl-70 in SSc patient (228.43 and 43.88) by using Mann-
Whitney U test the data revealed non significantly difference (P<0.001) than that control group as shown in table 
(1, 2). 
Table 1: The median and mean rank values of Serum Scl-70 in both SSc patients and control subjects 
 Groups Median Mean Rank P value 
Serum Scl-70 
ng⁄ml  
patients 215.91 51.80              <0.001 
(HS) Control 169.27 29.20 
HS: Highly significant 
P< 0.001 
 
Table 2: The median and mean rank values of Salivary Scl-70 in both SSc patients and control subjects. 
 Groups Median Mean Rank P value 
Saliva Scl-70 ng⁄ml 
patients 228.43 43.88 
0.194 
Control 220.96 37.13 
The mean level of serum anti-SSA in SSc patients (140.4 ± 22.67) which was significantly increased 
(P<0.05) than that control group (113.1 ± 18.01) ng/ml by using t-test. The mean level of salivary anti-SSA in SSc 
patient (145.5 ± 19.98) ng/ml was significantly increase by using t-test than that control group (111.5 ± 15.47) 
ng/ml, as shown in table (3, 4) and figure (1). 
In present study serum and salivary Anti Ro/SSA significant increase. In previous great, multicenter 
cohort study, were found that anti-Ro52 antibodies detected in “20% of 963” patients, making them the second 
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most common autoantibodies in systemic sclerosis, as well as overlapped with other disease specific auto reactive 
antibodies (Hudson et al., 2012). 
In present study was found highly significantly increased Scl-70, anti-SSA antibodies in saliva SSc 
patient that parallel with previous studies were showed that the presence of “circulating IgG class antibodies to 
citrullinated peptides (IgG-ACPA)” was extremely specific for rheumatoid arthritis (RA) (Van der Woude et al., 
2010).  
Table 3: The mean values of different Serum anti-SSA in both SSc patients and control subjects.  
  
SSc (N=40) Control (N=40)  
mean SD mean SD t-test P-value 
Serum anti-SSA  
ng⁄dl 
140.4 22.67 113.1 18.01 2.569 
0.011 
(S) 
S: Significant 
P< 0.05 
 
Table 4: The mean values of different Salivary SSA in both SSc patients and control subjects. 
 
SSc (N=40) Control (N=40)  
mean SD mean SD t-test P-value 
Saliva anti-SSA   
ng⁄dl 
145.5 19.98 111.5 15.47 3.459 
0.014 
(S) 
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